Clinical Trial Update: NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for NC-6004 in combination with 5-FU and cetuximab in recurrent/metastatic squamous cell carcinoma of the head and neck (Phase 1/2; comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• 5-FU (5-fluorouracil)
• Cetuximab (cetuximab)
• NC-6004 (cisplatin nanoparticle formulation)

Snippet

Sponsor: NanoCarrier Co., Ltd. | Conditions: Carcinoma, Squamous Cell of Head and Neck | Phase 1, Phase 2 | Status: COMPLETED